The NHLBI has launched a Strategic Visioning process to gather ideas for the most compelling scientific priorities to address over the next decade. Broad participation from the heart, lung, blood, and sleep research communities – scientists and patients alike - is vital to the success of this effort.
From the use of antibiotics to prevent and treat infections in children with sickle cell disease to the FDA approval of the drug hydroxyurea, researchers have made steady progress during the last few decades in improving the lives of individuals with sickle cell disease. Yet still, a widely available cure has remained just out of reach. Now, work from a team of researchers at the National Institutes of Health, including NHLBI's Dr. John Tisdale may open the door to reversing sickle cell disease in more patients.